Open AccessCardiac Tolerability of Concurrent Administration of Trastuzumab and Anthracycline-Based Regimen as Adjuvant Chemotherapy for Breast Cancer
Author(s) -
Naoki Watanabe,
Shoko Otsuka,
Yoko Sasaki,
Reiko Shimojima,
Yoji Wani,
Kaori Uchino
Publication year - 2014
Publication title -
breast care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.767
H-Index - 30
eISSN - 1661-3805
pISSN - 1661-3791
DOI - 10.1159/000358754
Subject(s) - trastuzumab , medicine , epirubicin , anthracycline , cardiotoxicity , tolerability , ejection fraction , breast cancer , regimen , chemotherapy , oncology , cancer , heart failure , adverse effect
Retrospective analysis suggests that anthracycline-containing regimens may be superior to non-anthracycline-containing regimens in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer. However, both trastuzumab and anthracycline have cardiotoxicity, and it remains unclear how to use trastuzumab in combination with an anthracycline to curtail their cardiotoxicity.